Revance Therapeutics (NASDAQ:RVNC) Research Coverage Started at StockNews.com

StockNews.com began coverage on shares of Revance Therapeutics (NASDAQ:RVNC) in a report released on Tuesday. The firm issued a hold rating on the biopharmaceutical company’s stock.

RVNC has been the topic of a number of other research reports. Mizuho reduced their target price on Revance Therapeutics from $6.66 to $3.10 and set a “neutral” rating on the stock in a report on Tuesday, December 10th. Barclays reduced their target price on Revance Therapeutics from $7.00 to $3.00 and set an “equal weight” rating on the stock in a report on Monday, December 23rd. Finally, Needham & Company LLC reaffirmed a “hold” rating on shares of Revance Therapeutics in a report on Friday, January 17th. Nine investment analysts have rated the stock with a hold rating and one has given a buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average target price of $8.39.

Revance Therapeutics Price Performance

Shares of NASDAQ RVNC opened at $3.65 on Tuesday. The business has a 50 day moving average price of $3.61 and a two-hundred day moving average price of $4.28. Revance Therapeutics has a fifty-two week low of $2.30 and a fifty-two week high of $6.65. The firm has a market cap of $381.02 million, a PE ratio of -1.89 and a beta of 0.90.

Institutional Trading of Revance Therapeutics

Several hedge funds have recently made changes to their positions in the stock. CIBRA Capital Ltd bought a new stake in shares of Revance Therapeutics in the 4th quarter worth approximately $3,466,000. Alpine Global Management LLC acquired a new stake in Revance Therapeutics in the 4th quarter valued at approximately $37,000. Two Sigma Investments LP increased its position in Revance Therapeutics by 8.6% in the 4th quarter. Two Sigma Investments LP now owns 170,136 shares of the biopharmaceutical company’s stock valued at $517,000 after acquiring an additional 13,539 shares during the period. ProShare Advisors LLC increased its position in Revance Therapeutics by 19.3% in the 4th quarter. ProShare Advisors LLC now owns 75,252 shares of the biopharmaceutical company’s stock valued at $229,000 after acquiring an additional 12,155 shares during the period. Finally, Man Group plc increased its position in Revance Therapeutics by 47.8% in the 4th quarter. Man Group plc now owns 443,544 shares of the biopharmaceutical company’s stock valued at $1,348,000 after acquiring an additional 143,544 shares during the period. Institutional investors own 97.70% of the company’s stock.

About Revance Therapeutics

Revance Therapeutics, Inc, a biotechnology company, engages in the development, manufacture, and commercialization of neuromodulators for various aesthetic and therapeutic indications in the United States and internationally. The company’s lead drug candidate is DAXXIFY (DaxibotulinumtoxinA-lanm) for injection for the treatment of glabellar lines and cervical dystonia; has completed phase II clinical trials to treat upper facial lines, moderate or severe dynamic forehead lines, and moderate or severe lateral canthal lines; and has completed Phase II clinical trials for the treatment of adult upper limb spasticity and plantar fasciitis.